Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells an… Read more
Statera Biopharma Inc (STAB) - Total Liabilities
Latest total liabilities as of September 2022: $22.92 Million USD
Based on the latest financial reports, Statera Biopharma Inc (STAB) has total liabilities worth $22.92 Million USD as of September 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Statera Biopharma Inc - Total Liabilities Trend (2006–2022)
This chart illustrates how Statera Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Statera Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Statera Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YUEXIU TRANSPOR (GZ3.SG)
STU:GZ3
|
Germany | €21.65 Billion |
|
Avalanche International Corp
PINK:AVLP
|
USA | $2.90 Million |
|
SKYCITY ENTERT
BE:RX4
|
Germany | €1.48 Billion |
|
INDORAMA VEN -F-
MU:I93
|
Germany | €394.53 Billion |
|
WGHT WTCHER INTL (WW6.SG)
STU:WW6
|
Germany | €1.69 Billion |
|
Lloyds Enterprises Limited
NSE:LLOYDSENT
|
India | ₹13.78 Billion |
Liability Composition Analysis (2006–2022)
This chart breaks down Statera Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Statera Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Statera Biopharma Inc (2006–2022)
The table below shows the annual total liabilities of Statera Biopharma Inc from 2006 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $22.68 Million | 0.00% |
| 2021-12-31 | $22.68 Million | +383.38% |
| 2020-12-31 | $4.69 Million | +208.52% |
| 2019-12-31 | $1.52 Million | +65.21% |
| 2018-12-31 | $920.38K | -58.56% |
| 2017-12-31 | $2.22 Million | -28.57% |
| 2016-12-31 | $3.11 Million | -46.79% |
| 2015-12-31 | $5.84 Million | -99.87% |
| 2014-12-31 | $4.55 Billion | -65.29% |
| 2013-12-31 | $13.11 Billion | +13.80% |
| 2012-12-31 | $11.52 Billion | -67.61% |
| 2010-12-31 | $35.58 Billion | +166.46% |
| 2009-12-31 | $13.35 Billion | +220.38% |
| 2008-12-31 | $4.17 Billion | +129043.71% |
| 2007-12-31 | $3.23 Million | +291.99% |
| 2006-12-31 | $823.38K | -- |